News
News

Achillion Pharmaceuticals

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement alternative pathway (AP) in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system. We are actively assessing two clinical stage, oral factor D inhibitors, danicopan (ACH-4471) and, second-generation, ACH-5228 in Phase 2 and 1 studies, respectively.

Learn More

Events
Events

Complement Mediated Diseases

Our Science

Patients and Clinicians